TY - JOUR
T1 - Delivery of therapeutics to the inner ear
T2 - The challenge of the blood-labyrinth barrier
AU - Nyberg, Sophie
AU - Joan Abbott, N.
AU - Shi, Xiaorui
AU - Steyger, Peter S.
AU - Dabdoub, Alain
N1 - Funding Information:
This work was supported by the Koerner Foundation (A.D.) and the Sunnybrook Hearing Regeneration Initiative (A.D. and S.N.), as well as NIDCD R01 grant nos. DC004555 and DC12588 (P.S.S.), NIH/NIDCD R21 grant no. DC016157 (X.S.), and NIH/NIDCD R01 DC015781 (X.S.).
Publisher Copyright:
Copyright © 2019 The Authors.
PY - 2019
Y1 - 2019
N2 - Permanent hearing loss affects more than 5% of the world’s population, yet there are no nondevice therapies that can protect or restore hearing. Delivery of therapeutics to the cochlea and vestibular system of the inner ear is complicated by their inaccessible location. Drug delivery to the inner ear via the vasculature is an attractive noninvasive strategy, yet the blood-labyrinth barrier at the luminal surface of inner ear capillaries restricts entry of most blood-borne compounds into inner ear tissues. Here, we compare the blood-labyrinth barrier to the blood-brain barrier, discuss invasive intratympanic and intracochlear drug delivery methods, and evaluate noninvasive strategies for drug delivery to the inner ear.
AB - Permanent hearing loss affects more than 5% of the world’s population, yet there are no nondevice therapies that can protect or restore hearing. Delivery of therapeutics to the cochlea and vestibular system of the inner ear is complicated by their inaccessible location. Drug delivery to the inner ear via the vasculature is an attractive noninvasive strategy, yet the blood-labyrinth barrier at the luminal surface of inner ear capillaries restricts entry of most blood-borne compounds into inner ear tissues. Here, we compare the blood-labyrinth barrier to the blood-brain barrier, discuss invasive intratympanic and intracochlear drug delivery methods, and evaluate noninvasive strategies for drug delivery to the inner ear.
UR - http://www.scopus.com/inward/record.url?scp=85062602519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062602519&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aao0935
DO - 10.1126/scitranslmed.aao0935
M3 - Article
C2 - 30842313
AN - SCOPUS:85062602519
SN - 1946-6234
VL - 11
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 482
M1 - eaao0935
ER -